bluebird bio, Inc. (NASDAQ:BLUE) Receives $4.63 Consensus PT from Analysts

bluebird bio, Inc. (NASDAQ:BLUE) has received a consensus rating of “Hold” from the twelve research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $4.63.

Several research firms have recently weighed in on BLUE. Robert W. Baird reduced their price objective on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday, August 15th. StockNews.com assumed coverage on shares of bluebird bio in a research report on Saturday, October 5th. They issued a “sell” rating on the stock. Wells Fargo & Company dropped their price objective on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Wednesday, September 25th. Cantor Fitzgerald reiterated a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price target on shares of bluebird bio in a research note on Thursday, August 15th.

bluebird bio Price Performance

Shares of NASDAQ:BLUE opened at $0.49 on Friday. The company has a market cap of $54.09 million, a price-to-earnings ratio of -0.67 and a beta of 0.75. The business has a 50 day moving average price of $0.64 and a 200 day moving average price of $0.90. The company has a quick ratio of 0.82, a current ratio of 0.93 and a debt-to-equity ratio of 0.20. bluebird bio has a twelve month low of $0.45 and a twelve month high of $5.53.

Institutional Trading of bluebird bio

A number of large investors have recently bought and sold shares of the stock. Vestal Point Capital LP bought a new stake in shares of bluebird bio in the 4th quarter worth about $2,967,000. Ghisallo Capital Management LLC acquired a new stake in shares of bluebird bio during the fourth quarter worth approximately $4,347,000. Pennant Investors LP bought a new position in shares of bluebird bio in the fourth quarter valued at approximately $121,000. Masters Capital Management LLC acquired a new position in bluebird bio in the fourth quarter worth $1,380,000. Finally, Virtu Financial LLC acquired a new stake in bluebird bio in the 4th quarter valued at about $317,000. 87.43% of the stock is currently owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.